Xinju Xiaogao Prescription Study on Overweight (XJXG)
Xinju Xiaogao Prescription and 10% of it in the Treatment of Adiposity (Stagnation of QI Causing Phlegm Retention)Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18-60 years old
- BMI≥28kg/m2,but<40kg/m2
- Waistline≥85cm(male),≥80cm(female)
- Pathoglycemia must fulfill one of those four condition:
- IGT,7.8≤2hPG≤11.0mmol/,
- diabetics take medicine used to treat type 2 diabetes more than 3 month,and 5.6≤FBG≤12.2,and weight change under 4kg.
- stagnation of QI causing phlegm retention
- To sign informed consent.
Exclusion Criteria:
- After 3-6 months simply controlling their diet and more exercise treatment, body weight weight loss ≥ 5%.
- TG>4.5mmol/L.
- Suffering from congenital heart disease, rheumatic heart disease, kidney disease, serious active liver disease, peptic ulcer disease or malabsorption syndrome.
- There is a history of pancreatitis or endocrine diseases other than diabetes, diabetes treated with insulin.
- Not suffered myocardial infarction in Past 3 months or unstable angina were confirmed.
- Had been diagnosed as "post-surgical adhesions" .
- There is a history of appetite or abuse of laxatives
- Diastolic blood pressure,uncontrolled or controlled, three times greater than 105mmHg .
- Pregnancy, prepare to pregnant or lactating women prepare.
- Allergies to Chinese medicine , allergic.
- Recurrent gallstone or a history of kidney stones.
- Mentally ill.
- Cancer patients.
- A history of gastrointestinal surgery to lose weight.
- Receiving other clinical studies nearly 3 months.
- Alcohol and / or psychoactive substances, drug abusers and addicts.
- Taking other weight-reducing aid Close within one month
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: placebo
Dose treatment group, 10%
|
Therapeutic dose of 10%
|
|
Active Comparator: Xinju Xiaogao Prescription
treatment group
|
treatment group
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
waistline
Time Frame: up to 24 weeks
|
up to 24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Body Mass Index (BMI)
Time Frame: up to 24 weeks
|
up to 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Fenglian Li, PHD, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 19850701
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.